Dimiracetam, a bicyclic 2-pyrrolidinone derivative originally developed as cognition enhancer, is a member of the nootropic family for which anecdotal efficacy in models of neuropathic pain has been reported. Its antineuropathic activity was evaluated in established models of neuropathic pain induced by nerve injury, chemotherapy or MIA-induced osteoarthritis. Acutely, dimiracetam was very effective in models of antiretroviral drug induced painful neuropathy, oxaliplatin-induced hyperalgesia and in the MIA-osteoarthritis. Chronic dimiracetam dosing in the MIA and ART- induced models completely reverted hyperalgesia back to the level of healthy controls. Once reached, the maximal effect was maintained despite dose diminution and increased inter-dose interval. The effect of the last dose outlasted dimiracetam half-life longer than 12 times. In synaptosomal preparations, dimiracetam counteracted the NMDA-induced release of glutamate with highest potency in the spinal cord, possibly via NMDA receptor isoforms containing pH-sensitive GluN1 and GluN2A subunits. Dimiracetam appears to be a promising and safe treatment for neuropathic pain conditions for which there are very limited therapeutic options. © 2014 Elsevier Ltd. All rights reserved.
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain / R.G. Fariello, C. Ghelardini, L. Di Cesare Mannelli, G. Bonanno, A. Pittaluga, M. Milanese, P. Misiano, C. Farina. - In: NEUROPHARMACOLOGY. - ISSN 0028-3908. - 81(2014), pp. 85-94.
|Titolo:||Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain|
MISIANO, PAOLA (Penultimo)
|Parole Chiave:||Glutamate; Neuropathic pain; Nootropics|
|Settore Scientifico Disciplinare:||Settore CHIM/08 - Chimica Farmaceutica|
Settore BIO/10 - Biochimica
|Data di pubblicazione:||2014|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.neuropharm.2014.01.029|
|Appare nelle tipologie:||01 - Articolo su periodico|